Your session is about to expire
← Back to Search
Dazodalibep Dose 1 for Sjögren's Syndrome
Study Summary
This trial aims to study the impact of dazodalibep on symptoms reported by patients with Sjogren's Syndrome. Additionally, it will assess the effects of dazodalibep on
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the safety considerations associated with administering Dazodalibep Dose 1 to patients?
"Based on the phase of this trial and the available safety data, our team at Power rates Dazodalibep Dose 1 with a score of 3 in terms of safety."
Are participants currently being enrolled in this study?
"Indeed, data from clinicaltrials.gov shows that this investigation is actively enrolling participants. The trial was initially listed on March 11th, 2024 and last modified on April 2nd, 2024. Approximately 435 individuals are sought across four designated locations."
Are there multiple testing facilities conducting this trial in Canada?
"Four clinical trial sites are currently enrolling participants, such as Shores Rheumatology in Saint Clair Shores and Arthritis, Rheumatic & Bone Disease Associates - P in Voorhees. Additionally, the Amarillo Center For Clinical Research - ClinEdge - PPDS is actively recruiting patients in Amarillo. There are also four more locations where patients can enroll for this study."
How many individuals are partaking in this clinical trial as participants overall?
"The study demands a cohort of 435 individuals meeting the defined eligibility criteria. Horizon Pharma Ireland, Ltd., headquartered in Dublin, Ireland, will oversee operations at various sites such as Shores Rheumatology in Saint Clair Shores, Michigan and Arthritis, Rheumatic & Bone Disease Associates - P in Voorhees, New jersey."
Share this study with friends
Copy Link
Messenger